Form 4: Daxor Corp Director Henry D. Cremisi Granted Stock Options

Director Henry D. Cremisi of Daxor Corp reports the acquisition of stock options contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Summary

• Henry D. Cremisi, a director of Daxor Corp, filed a Form 4 indicating a transaction involving derivative securities.
• On July 15, 2024, Cremisi was granted stock options to purchase 2,500 shares of Daxor Corp common stock at an exercise price of $9.20.
• The grant is contingent upon the SEC's approval to amend the Daxor Corporation 2020 Incentive Compensation Plan.
• The stock options vest in three installments: 833 on July 15, 2024, 833 on July 15, 2025 and 834 on July 15, 2026.
• The options expire on July 15, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, but the contingency on SEC approval adds a slight element of uncertainty.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company for the long term.

Risks

• The stock option grant is contingent on SEC approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan; failure to obtain this approval would nullify the grant.

Industry Context

Stock option grants are a common form of executive compensation, particularly in publicly traded companies, to align management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the healthcare industry, often used to incentivize performance and retain key personnel.
• The vesting schedule of three years is typical for stock options, aligning with industry norms for long-term incentives.
• The exercise price of $9.20 will be compared to the market price of DXR stock at the time of vesting to determine the value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• Employees may see the grant as a positive sign of the company's commitment to incentivizing its leadership.

Next Steps

• Daxor Corp will need to obtain SEC approval for the amendment to the 2020 Incentive Compensation Plan.
• Henry Cremisi will need to monitor the vesting schedule and exercise the options if he chooses to do so.

Key Dates